FDA Approves Xeomin as a Cosmetic Injectable
(FDA aprueba Xeomin como injectable cosmético) I’ve been treating my patients using Botox® and Dysport® to lessen the effects of facial wrinkles for many years with great success.
Now, with the recent FDA approval of Xeomin® for cosmetic use, I am pleased to offer a third alternative. This is not a new drug in the marketplace. Prior to this most recent FDA approval, Xeomin® had already been approved for medical usage and at this writing is in use in twenty countries. As such, Xeomin® has an established track record as an effective treatment for Cervial Dystonia, a disorder characterized by abnormal neck pain and movements, and Blepharospsm, which is marked by abnormal, involuntary blinking of the eyelids. Like other drugs in this category, Xeomin® works by blocking the signals from the nerves to the muscles so the targeted muscles contract less. Botox®, Dysport® and Xeomin® have a lot in common, but they also have some important differences. Unlike its predecessors, Xeomin® vials do not need to be refrigerated and contains no “accessory proteins”, the proteins that surround the active protein, or “botulinum toxin type A toxin”, as is the case in nature. This may lessen the patient’s likelihood of developing antibodies to Xeomin® and potentially eliminate the effect of the treatment. Perhaps the greatest benefit my patients will see with this new product is an influx of data from patients saying the effects of Xeomin® last longer than Botox® or Dysport®. As an established “key opinion leader” for Merz Pharmaceuticals, the makers of Xeomin®, I have been approved as one of only a few injectors for the preliminary cosmetic usage release of Xeomin®. I will be testing this theory when my trials begin in the spring of 2012. I’ll keep you posted as to my findings. Dr. Hevia is a renowned Miami cosmetic dermatologist.